> Details

Chalouhi, Nohra; Daou, Badih; Okabe, Toshimasa; Starke, Robert M.; Dalyai, Richard; Bovenzi, Cory D.; Anderson, Eliza Claire; Barros, Guilherme; Reese, Adam; Jabbour, Pascal; Tjoumakaris, Stavropoula; Rosenwasser, Robert; Kraft, Walter K.; Rincon, Fred

Beta-blocker therapy and impact on outcome after aneurysmal subarachnoid hemorrhage: a cohort study

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Beta-blocker therapy and impact on outcome after aneurysmal subarachnoid hemorrhage: a cohort study
  • Contributor: Chalouhi, Nohra; Daou, Badih; Okabe, Toshimasa; Starke, Robert M.; Dalyai, Richard; Bovenzi, Cory D.; Anderson, Eliza Claire; Barros, Guilherme; Reese, Adam; Jabbour, Pascal; Tjoumakaris, Stavropoula; Rosenwasser, Robert; Kraft, Walter K.; Rincon, Fred
  • imprint: Journal of Neurosurgery Publishing Group (JNSPG), 2016
  • Published in: Journal of Neurosurgery
  • Language: Not determined
  • DOI: 10.3171/2015.7.jns15956
  • ISSN: 0022-3085; 1933-0693
  • Keywords: General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>Cerebral vasospasm (cVSP) is a frequent complication of aneurysmal subarachnoid hemorrhage (aSAH), with a significant impact on outcome. Beta blockers (BBs) may blunt the sympathetic effect and catecholamine surge associated with ruptured cerebral aneurysms and prevent cardiac dysfunction. The purpose of this study was to investigate the association between preadmission BB therapy and cVSP, cardiac dysfunction, and in-hospital mortality following aSAH.</jats:p></jats:sec> <jats:sec> <jats:title>METHODS</jats:title> <jats:p>This was a retrospective cohort study of patients with aSAH who were treated at a tertiary high-volume neurovascular referral center. The exposure was defined as any preadmission BB therapy. The primary outcome was cVSP assessed by serial transcranial Doppler with any mean flow velocity ≥ 120 cm/sec and/or need for endovascular intervention for medically refractory cVSP. Secondary outcomes were cardiac dysfunction (defined as cardiac troponin-I elevation &gt; 0.05 μg/L, low left ventricular ejection fraction [LVEF] &lt; 40%, or LV wall motion abnormalities [LVWMA]) and in-hospital mortality.</jats:p></jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>The cohort consisted of 210 patients treated between February 2009 and September 2010 (55% were women), with a mean age of 53.4 ± 13 years and median Hunt and Hess Grade III (interquartile range III–IV). Only 13% (27/210) of patients were exposed to preadmission BB therapy. Compared with these patients, a higher percentage of patients not exposed to preadmission BBs had transcranial Doppler-mean flow velocity ≥ 120 cm/sec (59% vs 22%; p = 0.003). In multivariate analyses, lower Hunt and Hess grade (OR 3.9; p &lt; 0.001) and preadmission BBs (OR 4.5; p = 0.002) were negatively associated with cVSP. In multivariate analysis, LVWMA (OR 2.7; p = 0.002) and low LVEF (OR 1.1; p = 0.05) were independent predictors of in-hospital mortality. Low LVEF (OR 3.9; p = 0.05) independently predicted medically refractory cVSP. The in-hospital mortality rate was higher in patients with LVWMA (47.4% vs 14.8%; p &lt; 0.001).</jats:p></jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>The study data suggest that preadmission therapy with BBs is associated with lower incidence of cVSP after aSAH. LV dysfunction was associated with higher medically refractory cVSP and in-hospital mortality. BB therapy may be considered after aSAH as a cardioprotective and cVSP preventive therapy.</jats:p></jats:sec>
  • Access State: Open Access